Company has potential to solve large scale vaccination delivery issues to underserved populations worldwide, removing the negatives of sharp disposal, dosage, and pain.
LAKEFIELD, ON, April 2, 2020 /CNW/ - PKA SoftTouch Corp. of Lakefield, ON, www.pkasofttouch.com, today launched a public equity crowdfunding campaign for its globally patented groundbreaking Micro-needle technology that may play a key role in delivering a vaccine to battle COVID-19.
"During this time of a global pandemic, the need to create fast painless vaccine delivery in pre-measured quantities has never been greater," says Dick Crawford, PKA Board Chair and CEO. "We need to move quickly."
On March 31, Prime Minister Justin Trudeau called for "made-in-Canada solutions" for desperately needed medical supplies in the face of COVID-19. During his daily briefing, the prime minister predicted "made-in-Canada supply chains" will emerge to get supplies into the hands of healthcare professionals.
Crawford says the thumb-sized Micro-Needle has the potential to deliver pain medication and insulin as well as vaccines and does so with painless delivery and instant disposability, eliminating fear, needle phobia and sharps disposal issues.
Meanwhile, in the global rush to create a vaccine against the coronavirus which is killing thousands around the world, 35 vaccine producers and academic institutions are fast-tracking clinical trials to meet the urgent need, according to a recent report in the Guardian.
The equity crowdfunding campaign, https://livewebinar.com/468-518-011, http://www.frontfundr.com/company/pka with an initial short-term funding need of $412,000, will concentrate first on animal clinical trials, followed quickly by human clinical trials. The campaign is hosted by Vancouver-based equity crowdfunding platform Frontfundr. The campaign enables small investors to participate in the company's future growth prospects in a market estimated at $779 billion worldwide for vaccines prior to the onset of COVID-19.
The Micro-Needle works for both humans and animals, and the animal health drug market in Canada alone is on track to reach $1.3 billion by 2024, Crawford notes. "We are confident that once we pass the final clinical trials, pharmaceutical suppliers anxious to quickly retool manufacturing to produce the devices, will step forward to license our technology."
Clinical trials will be conducted at the University of Guelph, Ontario, and Southlake Regional Health Centre, Newmarket, Ontario.
SOURCE PKA SoftTouch Corp.
For further information: For information and interviews, contact: Dick Crawford, 705-652-1100, 705-761-9293 [email protected]